Singapore, Nov. 20 -- Global biopharma leader CSL has announced plans to expand its US presence over the next five years, resulting in approximately $1.5 billion in US capital investments. These investments will generate hundreds of high-quality American jobs, strengthen US manufacturing capabilities of plasma-derived therapies (PDTs), and help secure the US medicine supply chain. .

"The US is the world's leading source for plasma, the main component of plasma derived therapies," said Paul McKenzie, Chief Executive Officer and Managing Director, CSL. "These important medicines are often the most effective or only therapies available for many rare or serious diseases. By expanding our onshore production capacity in the U.S., we are deepen...